Top

BMC Urology

Published in:

Open Access 01-12-2020 | Biomarkers | Research article

Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review

Authors: F. Lozano, C. X. Raventos, A. Carrion, E. Trilla, J. Morote

Published in: BMC Urology | Issue 1/2020

Abstract

Background

Genetic biomarkers are a promising and growing field in the management of bladder cancer in all stages. The aim of this paper is to understand the role of genetic urinary biomarkers in the follow up of patients with non muscle invasive bladder cancer where there is increasing evidence that they can play a role in avoiding invasive techniques.

Methods

Following PRISMA criteria, we have performed a systematic review. The search yielded 164 unique articles, of which 21 articles were included involving a total of 7261 patients. Sixteen of the articles were DNA based biomarkers, analyzing different methylations, microsatellite aberrations and gene mutations. Five articles studied the role of RNA based biomarkers, based on measuring levels of different combinations of mRNA. QUADAS2 critical evaluation of each paper has been reported.

Results

There are not randomized control trials comparing any biomarker with the gold standard follow-up, and the level of evidence is 2B in almost all the studies. Negative predictive value varies between 55 and 98.5%, being superior in RNA based biomarkers.

Conclusions

Although cystoscopy and cytology are the gold standard for non muscle invasive bladder cancer surveillance, genetic urinary biomarkers are a promising tool to avoid invasive explorations to the patients with a safe profile of similar sensitivity and negative predictive value. The accuracy that genetic biomarkers can offer should be taken into account to modify the paradigm of surveillance in non muscle invasive bladder cancer patients, especially in high-risk ones where many invasive explorations are recommended and biomarkers experiment better results.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder Cancer across the European Union. Eur Urol. 2016;69(3):438–47. https://doi.org/10.1016/j.eururo.2015.10.024.CrossRefPubMed

Compérat E, Gontero P, Mostafid AH, Palou J, Van Rhijn BWG, Rouprêt M, et al. Non-muscle-invasive Bladder Cancer (TaT1 and CIS) EAU Guidelines; 2018. p. 1–48. Retrieved from http://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-muscle-invasive-Bladder-Cancer-TaT1-CIS-2018.pdf.

Daneshmand S, Konety BR. American urological association (AUA) guideline American urological association non-muscle invasive bladder Cancer. AUA Clinical Guidelines, (April); 2016. p. 1–45.

Burke DM, Shackley DC, O’Reilly PH. The community-based morbidity of flexible cystoscopy. BJU Int. 2002;89(4):347–9. https://doi.org/10.1046/j.1464-4096.2001.01899.x.CrossRefPubMed

Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int. 2006;97(5):997–1001. https://doi.org/10.1111/j.1464-410X.2006.06036.x.CrossRefPubMed

Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61(1):109–18. https://doi.org/10.1016/S0090-4295(02)02136-2.CrossRefPubMed

Bensalah K, Montorsi F, Shariat SF. Challenges of Cancer biomarker profiling {a figure is presented}. Eur Urol. 2007;52(6):1601–9. https://doi.org/10.1016/j.eururo.2007.09.036.CrossRefPubMed

Kamat AM, Karakiewicz PI, Xylinas E, Hegarty PK, Hegarty N, Jenkins LC, et al. ICUD-EAU international consultation on bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol. 2012;63(2013):4–15.PubMed

10.

Altman DG, McShane LM, Sauerbrei W, Taube SE, Cavenagh MM. REMARK (REporting recommendations for tumor MARKer prognostic studies). Guidelines for Reporting Health Research: A User’s Manual. 2014:241–9. https://doi.org/10.1002/9781118715598.ch23.

11.

Whiting, Penny F. ; Rutjes, Anne W.S.; Westwood, Marie E. ; Mallett, Susan ; Deeks, Jonathan J. ; Reitsma, Johannes B., ; Leeflang, Mariska M.G. ; Sterne, Jonathan A.C. ; Bossuyt, P. M. M. ; (2011). QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Internal Med Res RepMethods, 155(4), 529–536.

12.

Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. The BMJ. 2020;368:1–6. https://doi.org/10.1136/bmj.l6890.CrossRef

13.

Rouprêt M, Hupertan V, Yates DR, Comperat E, Catto JWF, Meuth M, et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int. 2008;101(11):1448–53. https://doi.org/10.1111/j.1464-410X.2008.07591.x.CrossRefPubMed

14.

van der Aa MNM, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA, et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive Urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (cost-effectiveness of follow-up of urinary bladder Cancer trial C). Eur Urol. 2009;55(3):659–68. https://doi.org/10.1016/j.eururo.2008.05.001.CrossRefPubMed

15.

Zuiverloon TCM, Van Der Aa MNM, Van Der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH, Zwarthoff EC. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle - invasive bladder cancer. Clin Cancer Res. 2010;16(11):3011–8. https://doi.org/10.1158/1078-0432.CCR-09-3013.CrossRefPubMed

16.

Reinert T, Borre M, Christiansen A, Hermann GG, Ørntoft TF, Dyrskjøt L. Diagnosis of bladder Cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation. PLoS One. 2012;7(10):1–9. https://doi.org/10.1371/journal.pone.0046297.CrossRef

17.

Zuiverloon TCM, Beukers W, Van Der Keur KA, Munoz JR, Bangma CH, Lingsma HF, et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int. 2012;109(6):941–8. https://doi.org/10.1111/j.1464-410X.2011.10428.x.CrossRefPubMed

18.

Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014;65(2):360–6. https://doi.org/10.1016/j.eururo.2013.08.052.CrossRefPubMed

19.

Abern MR, Owusu R, Inman BA. Clinical performance and utility of a DNA methylation urine test for bladder cancer. Urologic Oncol. 2014;32(1):51.e21–6. https://doi.org/10.1016/j.urolonc.2013.08.003.CrossRef

20.

Su S-F, de Castro Abreu AL, Chihara Y, Tsai Y, Andreu-Vieyra C, Daneshmand S, et al. A panel of three markers hyper- and Hypomethylated in urine sediments accurately predicts bladder Cancer recurrence. Clin Cancer Res. 2014;20(7):1978–89. https://doi.org/10.1158/1078-0432.CCR-13-2637.CrossRefPubMed

21.

Fantony JJ, Abern MR, Gopalakrishna A, Owusu R, Jack Tay K, Lance RS, Inman BA. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer. Urologic Oncol. 2015;33(9):387.e1–6. https://doi.org/10.1016/j.urolonc.2015.04.014.CrossRef

22.

Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, et al. FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder Cancer in a large prospective multicenter study. J Urol. 2017;197(6):1410–8. https://doi.org/10.1016/j.juro.2016.12.096.CrossRefPubMed

23.

Roperch JP, Grandchamp B, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, et al. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC Cancer. 2016;16(1):1–9. https://doi.org/10.1186/s12885-016-2748-5.CrossRef

24.

van der Heijden AG, Mengual L, Ingelmo-Torres M, Lozano JJ, van Rijt-van de Westerlo CCM, Baixauli M, et al. Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clin Epigenetics. 2018;10(1):1–10. https://doi.org/10.1186/s13148-018-0496-x.CrossRef

25.

Witjes JA, Morote J, Cornel EB, Gakis G, van Valenberg FJP, Lozano F, et al. Performance of the bladder EpiCheck™ methylation test for patients under surveillance for non–muscle-invasive bladder Cancer: results of a multicenter, prospective, blinded clinical trial. Eur Urol Oncol. 2018;1(4):307–13. https://doi.org/10.1016/j.euo.2018.06.011.CrossRefPubMed

26.

Springer SU, Chen CH, Del Carmen Rodriguez Pena M, Li L, Douville C, Wang Y, et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. ELife. 2018;7:1–27. https://doi.org/10.7554/eLife.32143.CrossRef

27.

D’Andrea D, Soria F, Zehetmayer S, Gust KM, Korn S, Witjes JA, Shariat SF. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. BJU Int. 2019;123(6):959–67. https://doi.org/10.1111/bju.14673.CrossRefPubMedPubMedCentral

28.

Batista R, Vinagre J, Prazeres H, Sampaio C, Peralta P, Conceição P, et al. Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-muscle-invasive bladder Cancer in a comprehensive multicenter study. Front Genet. 2019;10(December):1–15. https://doi.org/10.3389/fgene.2019.01237.CrossRef

29.

Sapre N, Macintyre G, Clarkson M, Naeem H, Cmero M, Kowalczyk A, et al. A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. Br J Cancer. 2016;114(4):454–62. https://doi.org/10.1038/bjc.2015.472.CrossRefPubMedPubMedCentral

30.

Kavalieris L, O’Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E, et al. Performance characteristics of a multigene urine biomarker test for monitoring for recurrent Urothelial carcinoma in a multicenter study. J Urol. 2017;197(6):1419–26. https://doi.org/10.1016/j.juro.2016.12.010.CrossRefPubMed

31.

Lotan Y, OʼSullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncol. 2017;35(8):531.e15–22. https://doi.org/10.1016/j.urolonc.2017.03.008.CrossRef

32.

Pichler R, Fritz J, Tulchiner G, Klinglmair G, Soleiman A, Horninger W, et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int. 2018;121(1):29–37. https://doi.org/10.1111/bju.14019.CrossRefPubMed

33.

Wallace E, Higuchi R, Satya M, McCann L, Sin MLY, Bridge JA, et al. Development of a 90-minute integrated noninvasive urinary assay for bladder Cancer detection. J Urol. 2018;199(3):655–62. https://doi.org/10.1016/j.juro.2017.09.141.CrossRefPubMed

34.

Mourah S, Cussenot O, Vimont V, Desgrandchamps F, Teillac P, Cochant-Priollet B, et al. Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. Int J Cancer. 1998;79(6):629–33. https://doi.org/10.1002/(SICI)1097-0215(19981218)79:6<629::AID-IJC13>3.0.CO;2-1.CrossRefPubMed

35.

Van Oers JMM, Lurkin I, Van Exsel AJA, Nijsen Y, Van Rhijn BWG, Van Der Aa MNM, Zwarthoff EC. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005;11(21):7743–8. https://doi.org/10.1158/1078-0432.CCR-05-1045.CrossRefPubMed

36.

Heller G, Babinsky VN, Ziegler B, Weinzierl M, Noll C, Altenberger C, et al. Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. Carcinogenesis. 2013;34(3):513–21. https://doi.org/10.1093/carcin/bgs363.CrossRefPubMed

37.

Kim JG, Takeshima H, Niwa T, Rehnberg E, Shigematsu Y, Yoda Y, et al. Comprehensive DNA methylation and extensive mutation analyses reveal an association between the CpG island methylator phenotype and oncogenic mutations in gastric cancers. Cancer Lett. 2013;330(1):33–40. https://doi.org/10.1016/j.canlet.2012.11.022.CrossRefPubMed

38.

Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 2006;25(7):1070–80. https://doi.org/10.1038/sj.onc.1209154.CrossRefPubMed

39.

Kelly TK, Jones PA, Sharma S. Epigenetics in cancer. Carcinogenesis. 2009;31(1):27–36. https://doi.org/10.1093/carcin/bgp220.CrossRefPubMedPubMedCentral

40.

Saxonov S, Berg P, D. L. B. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci. 2006;18(2):193–204. https://doi.org/10.1080/03071375.1994.9747015.CrossRef

41.

Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3(4):253–66. https://doi.org/10.1038/nrc1045.CrossRefPubMed

42.

Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res. 2011;17(17):5582–92. https://doi.org/10.1158/1078-0432.CCR-10-2659.CrossRefPubMed

43.

Serizawa RR, Ralfkiær U, Steven K, Lam GW, Schmiedel S, Schüz J, et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer. 2011;129(1):78–87. https://doi.org/10.1002/ijc.25651.CrossRefPubMed

44.

Kandimalla R, Van Tilborg AAG, Kompier LC, Stumpel DJPM, Stam RW, Bangma CH, Zwarthoff EC. Genome-wide analysis of CpG Island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur Urol. 2012;61(6):1245–56. https://doi.org/10.1016/j.eururo.2012.01.011.CrossRefPubMed

45.

Renard I, Joniau S, van Cleynenbreugel B, Collette C, Naômé C, Vlassenbroeck I, et al. Identification and validation of the methylated TWIST1 and NID2 genes through Real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder Cancer in urine samples. Eur Urol. 2010;58(1):96–104. https://doi.org/10.1016/j.eururo.2009.07.041.CrossRefPubMed

46.

Cancer T, Atlas G. Comprehensive molecular characterization of Urothelial bladder carcinoma:the Cancer genome Atlas research network. Nature. 2013;507(7492):315–22. https://doi.org/10.1038/nature12965.Comprehensive.CrossRef

47.

Billerey C, Chopin D, Bralet M, Lahaye J, Abbou CC, Bonaventure J, et al. Short Communication. 2001;158(6):1955–9.

48.

Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021–6. https://doi.org/10.1073/pnas.1303607110.CrossRefPubMedPubMedCentral

49.

Douville C, Springer S, Kinde I, Cohen JD, Hruban RH, Lennon AM, et al. Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs). Proc Natl Acad Sci U S A. 2018;115(8):1871–6. https://doi.org/10.1073/pnas.1717846115.CrossRefPubMedPubMedCentral

50.

Kiselev FL. MicroRNA and cancer. Mol Biol. 2014;48(2):232–42.

51.

Lotan Y, Shariat SF, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urologic Oncol. 2010;28(4):441–8. https://doi.org/10.1016/j.urolonc.2009.11.004.CrossRef

52.

Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21(35 REV. ISS. 3):5427–40. https://doi.org/10.1038/sj.onc.1205600.CrossRefPubMed

53.

van der Aa MNM, Steyerberg EW, Bangma C, van Rhijn BWG, Zwarthoff EC, van der Kwast TH. Cystoscopy revisited as the gold standard for detecting bladder Cancer recurrence: diagnostic review Bias in the randomized, prospective CEFUB trial. J Urol. 2010;183(1):76–80. https://doi.org/10.1016/j.juro.2009.08.150.CrossRefPubMed

54.

Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Sugano K, et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res. 2010;70(20):8169–78. https://doi.org/10.1158/0008-5472.CAN-10-1335.CrossRefPubMedPubMedCentral

Title: Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review
Authors: F. Lozano
C. X. Raventos
A. Carrion
E. Trilla
J. Morote
Publication date: 01-12-2020
Publisher: BioMed Central
Keyword: Biomarkers
Published in: BMC Urology / Issue 1/2020
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/s12894-020-00670-x

At a glance: The STEP trials

Springer Medicine

Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Contrast-enhanced transrectal ultrasound can reduce collection of unnecessary biopsies when diagnosing prostate cancer and is predictive of biochemical recurrence following a radical prostatectomy in patients with localized prostate cancer

Systemic inflammatory response syndrome in patients with acute obstructive upper tract urinary stone: a risk factor for urgent renal drainage and revisit to the emergency department

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study

miR-185 inhibits prostate cancer angiogenesis induced by the nodal/ALK4 pathway

Case report of sigmoid colon perforation and colocutaneous fistula due to retropubic midurethral sling placement for stress urinary incontinence